News / Life Sciences & Health

Duke clinical trial shows frontline immunotherapy can shrink MSS colorectal tumors

Duke’s small, first-line immunotherapy cohort produced rapid and deep tumor shrinkage in a subset of patients with microsatellite-stable colorectal cancer, renewing interest in non‑chemotherapy initial strategies. Key metrics: 15 patients , infusions every two weeks , and dramatic individual tumor count reductions that reframe patient selection and trial design.